K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells

Ryuichiro Nakai, Shin Ichi Iida, Takeshi Takahashi, Tetsuya Tsujita, Seiho Okamoto, Chie Takada, Kazuhito Akasaka, Shunji Ichikawa, Hiroyuki Ishida, Hideaki Kusaka, Shiro Akinaga, Chikara Murakata, Shinobu Honda, Masayuki Nitta, Hideyuki Saya, Yoshinori Yamashita

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The aim of this study was to investigate the mechanism of inhibition of Eg5 (kinesin spindle protein), a mitotic kinesin that plays an essential role in establishing mitotic spindle bipolarity, by the novel small molecule inhibitor K858. K858 was selected in a phenotype-based forward chemical genetics screen as an antimitotic agent, and subsequently characterized as an inhibitor of Eg5. K858 blocked centrosome separation, activated the spindle checkpoint, and induced mitotic arrest in cells accompanied by the formation of monopolar spindles. Long-term continuous treatment of cancer cells with K858 resulted in antiproliferative effects through the induction of mitotic cell death, and polyploidization followed by senescence. In contrast, treatment of nontransformed cells with K858 resulted in mitotic slippage without cell death, and cell cycle arrest in G1 phase in a tetraploid state. In contrast to paclitaxel, K858 did not induce the formation of micronuclei in either cancer or nontransformed cells, suggesting that K858 has minimal effects on abnormalities in the number and structure of chromosomes. K858 exhibited potent antitumor activity in xenograft models of cancer, and induced the accumulation of mitotic cells with monopolar spindles in tumor tissues. Importantly, K858, unlike antimicrotubule agents, had no effect on microtubule polymerization in cell-free and cellbased assays, and was not neurotoxic in a motor coordination test in mice. Taken together, the Eg5 inhibitor K858 represents an important compound for further investigation as a novel anticancer therapeutic.

Original languageEnglish
Pages (from-to)3901-3909
Number of pages9
JournalCancer Research
Volume69
Issue number9
DOIs
Publication statusPublished - 2009 May 1

Fingerprint

Kinesin
Antineoplastic Agents
Cell Death
Neoplasms
M Phase Cell Cycle Checkpoints
Chromosome Structures
Antimitotic Agents
Centrosome
Spindle Apparatus
Tetraploidy
G1 Phase
Paclitaxel
Cell Cycle Checkpoints
Heterografts
Microtubules
Polymerization
Phenotype
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakai, R., Iida, S. I., Takahashi, T., Tsujita, T., Okamoto, S., Takada, C., ... Yamashita, Y. (2009). K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Research, 69(9), 3901-3909. https://doi.org/10.1158/0008-5472.CAN-08-4373

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. / Nakai, Ryuichiro; Iida, Shin Ichi; Takahashi, Takeshi; Tsujita, Tetsuya; Okamoto, Seiho; Takada, Chie; Akasaka, Kazuhito; Ichikawa, Shunji; Ishida, Hiroyuki; Kusaka, Hideaki; Akinaga, Shiro; Murakata, Chikara; Honda, Shinobu; Nitta, Masayuki; Saya, Hideyuki; Yamashita, Yoshinori.

In: Cancer Research, Vol. 69, No. 9, 01.05.2009, p. 3901-3909.

Research output: Contribution to journalArticle

Nakai, R, Iida, SI, Takahashi, T, Tsujita, T, Okamoto, S, Takada, C, Akasaka, K, Ichikawa, S, Ishida, H, Kusaka, H, Akinaga, S, Murakata, C, Honda, S, Nitta, M, Saya, H & Yamashita, Y 2009, 'K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells', Cancer Research, vol. 69, no. 9, pp. 3901-3909. https://doi.org/10.1158/0008-5472.CAN-08-4373
Nakai, Ryuichiro ; Iida, Shin Ichi ; Takahashi, Takeshi ; Tsujita, Tetsuya ; Okamoto, Seiho ; Takada, Chie ; Akasaka, Kazuhito ; Ichikawa, Shunji ; Ishida, Hiroyuki ; Kusaka, Hideaki ; Akinaga, Shiro ; Murakata, Chikara ; Honda, Shinobu ; Nitta, Masayuki ; Saya, Hideyuki ; Yamashita, Yoshinori. / K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. In: Cancer Research. 2009 ; Vol. 69, No. 9. pp. 3901-3909.
@article{c7bd395c82f347b681e4d46775aac32a,
title = "K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells",
abstract = "The aim of this study was to investigate the mechanism of inhibition of Eg5 (kinesin spindle protein), a mitotic kinesin that plays an essential role in establishing mitotic spindle bipolarity, by the novel small molecule inhibitor K858. K858 was selected in a phenotype-based forward chemical genetics screen as an antimitotic agent, and subsequently characterized as an inhibitor of Eg5. K858 blocked centrosome separation, activated the spindle checkpoint, and induced mitotic arrest in cells accompanied by the formation of monopolar spindles. Long-term continuous treatment of cancer cells with K858 resulted in antiproliferative effects through the induction of mitotic cell death, and polyploidization followed by senescence. In contrast, treatment of nontransformed cells with K858 resulted in mitotic slippage without cell death, and cell cycle arrest in G1 phase in a tetraploid state. In contrast to paclitaxel, K858 did not induce the formation of micronuclei in either cancer or nontransformed cells, suggesting that K858 has minimal effects on abnormalities in the number and structure of chromosomes. K858 exhibited potent antitumor activity in xenograft models of cancer, and induced the accumulation of mitotic cells with monopolar spindles in tumor tissues. Importantly, K858, unlike antimicrotubule agents, had no effect on microtubule polymerization in cell-free and cellbased assays, and was not neurotoxic in a motor coordination test in mice. Taken together, the Eg5 inhibitor K858 represents an important compound for further investigation as a novel anticancer therapeutic.",
author = "Ryuichiro Nakai and Iida, {Shin Ichi} and Takeshi Takahashi and Tetsuya Tsujita and Seiho Okamoto and Chie Takada and Kazuhito Akasaka and Shunji Ichikawa and Hiroyuki Ishida and Hideaki Kusaka and Shiro Akinaga and Chikara Murakata and Shinobu Honda and Masayuki Nitta and Hideyuki Saya and Yoshinori Yamashita",
year = "2009",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-08-4373",
language = "English",
volume = "69",
pages = "3901--3909",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells

AU - Nakai, Ryuichiro

AU - Iida, Shin Ichi

AU - Takahashi, Takeshi

AU - Tsujita, Tetsuya

AU - Okamoto, Seiho

AU - Takada, Chie

AU - Akasaka, Kazuhito

AU - Ichikawa, Shunji

AU - Ishida, Hiroyuki

AU - Kusaka, Hideaki

AU - Akinaga, Shiro

AU - Murakata, Chikara

AU - Honda, Shinobu

AU - Nitta, Masayuki

AU - Saya, Hideyuki

AU - Yamashita, Yoshinori

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The aim of this study was to investigate the mechanism of inhibition of Eg5 (kinesin spindle protein), a mitotic kinesin that plays an essential role in establishing mitotic spindle bipolarity, by the novel small molecule inhibitor K858. K858 was selected in a phenotype-based forward chemical genetics screen as an antimitotic agent, and subsequently characterized as an inhibitor of Eg5. K858 blocked centrosome separation, activated the spindle checkpoint, and induced mitotic arrest in cells accompanied by the formation of monopolar spindles. Long-term continuous treatment of cancer cells with K858 resulted in antiproliferative effects through the induction of mitotic cell death, and polyploidization followed by senescence. In contrast, treatment of nontransformed cells with K858 resulted in mitotic slippage without cell death, and cell cycle arrest in G1 phase in a tetraploid state. In contrast to paclitaxel, K858 did not induce the formation of micronuclei in either cancer or nontransformed cells, suggesting that K858 has minimal effects on abnormalities in the number and structure of chromosomes. K858 exhibited potent antitumor activity in xenograft models of cancer, and induced the accumulation of mitotic cells with monopolar spindles in tumor tissues. Importantly, K858, unlike antimicrotubule agents, had no effect on microtubule polymerization in cell-free and cellbased assays, and was not neurotoxic in a motor coordination test in mice. Taken together, the Eg5 inhibitor K858 represents an important compound for further investigation as a novel anticancer therapeutic.

AB - The aim of this study was to investigate the mechanism of inhibition of Eg5 (kinesin spindle protein), a mitotic kinesin that plays an essential role in establishing mitotic spindle bipolarity, by the novel small molecule inhibitor K858. K858 was selected in a phenotype-based forward chemical genetics screen as an antimitotic agent, and subsequently characterized as an inhibitor of Eg5. K858 blocked centrosome separation, activated the spindle checkpoint, and induced mitotic arrest in cells accompanied by the formation of monopolar spindles. Long-term continuous treatment of cancer cells with K858 resulted in antiproliferative effects through the induction of mitotic cell death, and polyploidization followed by senescence. In contrast, treatment of nontransformed cells with K858 resulted in mitotic slippage without cell death, and cell cycle arrest in G1 phase in a tetraploid state. In contrast to paclitaxel, K858 did not induce the formation of micronuclei in either cancer or nontransformed cells, suggesting that K858 has minimal effects on abnormalities in the number and structure of chromosomes. K858 exhibited potent antitumor activity in xenograft models of cancer, and induced the accumulation of mitotic cells with monopolar spindles in tumor tissues. Importantly, K858, unlike antimicrotubule agents, had no effect on microtubule polymerization in cell-free and cellbased assays, and was not neurotoxic in a motor coordination test in mice. Taken together, the Eg5 inhibitor K858 represents an important compound for further investigation as a novel anticancer therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=65949093526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949093526&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-4373

DO - 10.1158/0008-5472.CAN-08-4373

M3 - Article

C2 - 19351824

AN - SCOPUS:65949093526

VL - 69

SP - 3901

EP - 3909

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -